TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency
Brief Summary: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.


Options:
A: N/A
B: To assess the safety of a single topical dose of PRT-201. To assess the effect on the diameter of and blood flow through the AVF outflow vein. (2 & 6 weeks after AVF creation)
C: Primary AVF patency. (12 months after AVF creation); Number of participants with adverse events as a measure of safety and tolerability of PRT-201. (12 months after AVF creation.)
D: Access flow monthly for 3 months and 6th month (0,1st,2nd,3rd and 6th months) and Echocardiographic parameters at 6th month ( 0 and 6th months) (6 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: Many overweight patients are able to lose weight successfully, but then regain their weight. The purpose of this study is to develop and test the efficacy of 2 interventions to prevent weight regain in individuals who have recently lost weight. The two interventions being tested are a face-to-face group maintenance program and an Internet intervention. These interventions will be compared to a no-contact control group that receives quarterly newsletters. The primary outcome measure is weight regain from baseline to 18-months.


Options:
A: Anthropometrics (body weight, height, circumferences, total body fat%, blood pressure); Energy intake (Food Frequency Questionnaire); Physical activity level (Physical Activity Scale for the Elderly)
B: N/A
C: Body Weight (1 year)
D: Change in Weight (Baseline to 30 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Depakote ER for the Treatment of Bipolar Disorder in Children and Adolescents
Brief Summary: The purpose of this study is to determine the safety and effectiveness of Depakote ER (Divalproex Sodium Extended-Release Tablets) compared to placebo in the treatment of bipolar disorder, manic or mixed type in children and adolescents ages 10-17 years.


Options:
A: Safety outcome measures
B: Clinical Global Impressions-Bipolar Mania Improvement (Measured at Week 8)
C: Young Mania Rating Scale (YMRS) (Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).)
D: Change from baseline to the final evaluation in Y-MRS score.

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia
Brief Summary: The purpose of this study is to determine if intravenous micronutrient therapy (IVMT) is effective in the treatment of fibromyalgia, as assessed by validated functional and pain measures.


Options:
A: Endpoint mean pain score derived from the subject's daily pain diary (Endpoint); Patient Global Assessment (Patient Global Impression of Change) at Termination Visit (Weeks 5 and 13); Change from baseline in functioning (score created from the Short Form-36 [SF-36] Social and Physical Functioning, Fibromyalgia Impact Questionnaire [FIQ]-Total Score, and Sheehan Disability Scale [SDS] Total Score) at Termination Visit (Baseline and Weeks 5, 9, and 13)
B: Percentage of Participants With Less Than 11 Tender Points at Month 6 (Month 6); Percentage of Participants With Less Than 11 Tender Points at Month 12 (Month 12)
C: reduction number of tender points (paired) (one year treatment)
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Family Planning Promotion to Prevent Unplanned Pregnancies in HIV Infected Zambian Couples
Brief Summary: Prevention of unplanned pregnancies among HIV infected couples decreases the rate of maternal-child virus transmission and the number of children orphaned when parents die of AIDS. This study will evaluate two programs for reducing the number of unplanned pregnancies among HIV infected couples in Zambia.


Options:
A: Contraceptive use at time of last sexual intercourse (18 months)
B: Sequence-verified HIV-transmission from index to partner participant (March 2009)
C: Measurement of contraceptive adherence (12 months); Measurement of dual method use (12 months); Measurement of pregnancy rates and sexually transmitted diseases (STDs) (12 months)
D: pregnancy

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Family Planning Promotion to Prevent Unplanned Pregnancies in HIV Infected Zambian Couples
Brief Summary: Prevention of unplanned pregnancies among HIV infected couples decreases the rate of maternal-child virus transmission and the number of children orphaned when parents die of AIDS. This study will evaluate two programs for reducing the number of unplanned pregnancies among HIV infected couples in Zambia.


Options:
A: pregnancy
B: Sequence-verified HIV-transmission from index to partner participant (March 2009)
C: HIV sero-incidence (24 months post-baseline)
D: Unintended pregnancies (24 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Lifestyle Changes to Increase Bone Density in Teen Girls
Brief Summary: Osteoporosis affects nearly half of all American women over age 50. During the teenage years, girls can increase bone growth to decrease their risk of osteoporosis later in life. This study will test whether girls can change their food intake and physical activity patterns in ways that will increase their bone growth during the mid-teen years.


Options:
A: Body mass index (Baseline, 3 and 6 months)
B: Our outcome measure was reduction of screen time (4 waves of data)
C: Total Body Bone Mineral Density (TBBMD) (Baseline, 1 year, and 2 years)
D: N/A

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Incorporating More Physical Activity and Calcium in Teens (IMPACT): A School-Based Osteoporosis Prevention Program for Adolescent Girls
Brief Summary: The Incorporating More Physical Activity and Calcium in Teens (IMPACT) study was a behaviorally-based middle school nutrition and physical activity program for the prevention of osteoporosis. The goal of IMPACT was to increase calcium intake and physical activity to help build bone mass in girls.


Options:
A: Percent Body Fat (Baseline and One year)
B: Overweight and obesity according to IOTF references (0-1-2 years)
C: BMI and aerobic fitness (1 schoolyear)
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
Brief Summary: The purpose of the study is to assess the efficacy, safety and tolerability of NGX 4010 applied for 60 minutes for the treatment of PHN.


Options:
A: The Primary Measure of Efficacy Was the Percent Change in the "Average Pain for the Past 24 Hours" Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to 12. (Weeks 2-12)
B: N/A
C: Percent change from baseline in the "average pain for the past 24 hours" Numeric Pain Rating Scale (NPRS) score (i.e., average of scores during Weeks 2-12, compared to baseline)
D: Percent change from baseline in "average pain for the past 24 hours" Numeric Pain Rating Scale (NPRS) score (i.e., average of scores during Weeks 2 to 8, compared to baseline) in the active group compared to the control group

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Brief Summary: RATIONALE: Goserelin blocks hormone production in the ovaries. It is not yet known whether ovarian suppression using goserelin will prevent ovarian failure (early menopause) in women receiving chemotherapy for breast cancer.

PURPOSE: This randomized phase III trial is studying how well giving goserelin together with chemotherapy works compared with chemotherapy alone in preventing early menopause in women with stage I, stage II, or stage IIIA breast cancer.


Options:
A: Rate of Premature Ovarian Failure at 2 Years (2 years)
B: Chemotherapy-induced early menopause as measured by follicle-stimulating hormone, 17 beta estradiol levels, and menstrual activity resumption at 1 year following the completion of chemotherapy
C: Disease-free Survival (5-year estimate reported at a median follow-up of 72 months)
D: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Investigational Vertebroplasty Efficacy and Safety Trial (INVEST)
Brief Summary: Vertebroplasty is a procedure used to stabilize broken vertebrae, the bones that form the spine. This study will evaluate the effectiveness of vertebroplasty for the treatment of fractures due to osteoporosis.


Options:
A: Impact into quality of life with the Qualeffo-41 test (Baseline, 2 weeks, 2 months, 6 months and 1 year)
B: Back-specific Functional Status Using Roland-Morris Disability Questionnaire (RDQ) Scale at 1 Month (1 month after procedure); Patient's Rating of Average Pain at 1 Month (1 month)
C: Patient rated pain intensity (two weeks)
D: Back specific functional status(Roland) (12 mo); Pain (12 mo)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Investigational Vertebroplasty Efficacy and Safety Trial (INVEST)
Brief Summary: Vertebroplasty is a procedure used to stabilize broken vertebrae, the bones that form the spine. This study will evaluate the effectiveness of vertebroplasty for the treatment of fractures due to osteoporosis.


Options:
A: pain relief (12 months)
B: To compare the cost-effectivity in the two groups (1 month, 1 year); VAS score in time (1 month, 1 year)
C: Back-specific Functional Status Using Roland-Morris Disability Questionnaire (RDQ) Scale at 1 Month (1 month after procedure); Patient's Rating of Average Pain at 1 Month (1 month)
D: Patient rated pain intensity (two weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of a Novel Oral Contraceptive Initiation Method
Brief Summary: Women who choose to take birth control pills are currently instructed to begin taking the pills at the end of a menstrual cycle. This creates a window of time between when the woman is given the pills and when she begins taking them. Some women fail to begin taking the pills, placing them at increased risk of pregnancy. This study will evaluate a new approach to beginning birth control pills. Women will take the first pill in the doctor's office rather than waiting until the next menstrual cycle.


Options:
A: Use of a Effective Contraceptive Method at Four-months Post-abortion (4 months)
B: contraceptive continuation (6 months)
C: N/A
D: Contraceptive use at time of last sexual intercourse (18 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of a Novel Oral Contraceptive Initiation Method
Brief Summary: Women who choose to take birth control pills are currently instructed to begin taking the pills at the end of a menstrual cycle. This creates a window of time between when the woman is given the pills and when she begins taking them. Some women fail to begin taking the pills, placing them at increased risk of pregnancy. This study will evaluate a new approach to beginning birth control pills. Women will take the first pill in the doctor's office rather than waiting until the next menstrual cycle.


Options:
A: N/A
B: 12 month cumulative COC discontinuation probabilities (12 months)
C: contraceptive continuation (6 months)
D: Pearl Index (Up to 1 year)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of a Novel Oral Contraceptive Initiation Method
Brief Summary: Women who choose to take birth control pills are currently instructed to begin taking the pills at the end of a menstrual cycle. This creates a window of time between when the woman is given the pills and when she begins taking them. Some women fail to begin taking the pills, placing them at increased risk of pregnancy. This study will evaluate a new approach to beginning birth control pills. Women will take the first pill in the doctor's office rather than waiting until the next menstrual cycle.


Options:
A: Bleeding pattern (7 treatment cycles each consisting of 28 days); Number of unintended pregnancies (7 treatment cycles each consisting of 28 days and follow-up period of 14 days)
B: Impact on metabolic parameters (e.g. hemostatic parameters) after 6 month treatment (Baseline, Cycle 7)
C: Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) (1 year (13 cycles)); Number of In-treatment Pregnancies (With +14 Day Window) Per 100 Woman Years of Exposure (Pearl Index) (1 year (13 cycles))
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome
Brief Summary: Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting up to 10% of women. The primary symptoms of PCOS are menstrual irregularities, increased body and facial hair, acne, and infertility. This study will test a combination of medications in women with PCOS to determine which works best to overcome infertility.


Options:
A: The main outcome was change in body weight. (Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial.)
B: Live birth rate
C: Change in Testosterone After 6 Months of Treatment (baseline and 6 months)
D: Clinical pregnancy (within 6 calendar months of randomisation)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome
Brief Summary: Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting up to 10% of women. The primary symptoms of PCOS are menstrual irregularities, increased body and facial hair, acne, and infertility. This study will test a combination of medications in women with PCOS to determine which works best to overcome infertility.


Options:
A: Serum testosterone
B: Live birth rate
C: Change in Testosterone After 6 Months of Treatment (baseline and 6 months)
D: serum testosterone

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome
Brief Summary: Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting up to 10% of women. The primary symptoms of PCOS are menstrual irregularities, increased body and facial hair, acne, and infertility. This study will test a combination of medications in women with PCOS to determine which works best to overcome infertility.


Options:
A: Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH. (Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks)
B: To investigate whether four months of Metformin treatment before IVF (in-vitro-fertilisation) or ICSI (intra-cytoplasmic sperm injection) will increase clinical pregnancy rate in normal weight PCOS-women (Vaginal ultrasound in pregnancy week 7)
C: Live birth rate
D: Clinical pregnancy (within 6 calendar months of randomisation)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Skills Training, Exposure, and Their Combination in Childhood Abuse PTSD
Brief Summary: This study will compare one- and two-component treatments in women with post-traumatic stress disorder (PTSD).


Options:
A: PTSD diagnosis and severity score according to the Clinicians Administered PTSD Scale (CAPS) (4 & 9 months after completion of treatment)
B: summing totals of 17 DSM-IV symptoms (10 weeks)
C: PTSD symptom score (baseline, after MBSR and 4 months later)
D: outcome (within study timeframe)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Brief Summary: Gestational diabetes mellitus (GDM) is a type of diabetes (high blood sugar) that occurs in pregnant women. This study will determine whether treating pregnant women who have mild GDM improves the health of their babies. The follow-up study will examine whether factors during the previous pregnancy (such as blood sugar during pregnancy) are associated with the woman and her child's health 4-9 years later.


Options:
A: 3rd trimester glycated hemoglobin (3rd trimester of pregnancy); total maternal weight gain (during pregnancy); severe maternal hypoglycemia (from enrollment to delivery); preeclampsia (during pregnancy or puerperium); cesarean section (at the end of pregnancy); gestational age at birth (at birth); preterm birth (at birth); birthweight (at birth); macrosomia (at birth); large-for-gestational age newborn (at birth); small-for-gestational age newborn (at birth); neonatal hypoglycemia (in the neonatal period); perinatal mortality (in the perinatal period); insulin treatment (from enrollment to delivery)
B: Number of Participants With Composite Neonatal Morbidity (Delivery through discharge of infant from hospital up to 120 days); Number of Children at the 5-10 Year Followup With BMI ≥ 95th Percentile for Age and Sex (Age 5-10 years)
C: Need of insulin treatment for GDM (Day of delivery)
D: Gestational diabetes (20 and 36 weeks pregnancy and 3 months post partum); Gestational diabetes (18 months postpartum)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Brief Summary: Gestational diabetes mellitus (GDM) is a type of diabetes (high blood sugar) that occurs in pregnant women. This study will determine whether treating pregnant women who have mild GDM improves the health of their babies. The follow-up study will examine whether factors during the previous pregnancy (such as blood sugar during pregnancy) are associated with the woman and her child's health 4-9 years later.


Options:
A: Glycosylated haemogloblin (8 weeks from recruitment at 28 weeks gestation to 36 weeks gestation)
B: Number of Participants With Composite Neonatal Morbidity (Delivery through discharge of infant from hospital up to 120 days); Number of Children at the 5-10 Year Followup With BMI ≥ 95th Percentile for Age and Sex (Age 5-10 years)
C: Patient satisfaction (At 36-39 weeks gestation); Health care staff satisfaction (At completion of the study estimated to be January 2013); Management decision comparison (At weekly clinic or telemonitoring review from time recruited into study to delivery, estimated at an average of twelve weeks.)
D: Framingham 10-year risk index (1 year)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Brief Summary: Gestational diabetes mellitus (GDM) is a type of diabetes (high blood sugar) that occurs in pregnant women. This study will determine whether treating pregnant women who have mild GDM improves the health of their babies. The follow-up study will examine whether factors during the previous pregnancy (such as blood sugar during pregnancy) are associated with the woman and her child's health 4-9 years later.


Options:
A: Gestational diabetes diagnosis assessed through glucose tolerance test. (28 weeks gestational age)
B: Number of Participants With Composite Neonatal Morbidity (Delivery through discharge of infant from hospital up to 120 days); Number of Children at the 5-10 Year Followup With BMI ≥ 95th Percentile for Age and Sex (Age 5-10 years)
C: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)
D: Serum fasting glucose values. (Fasting glucose will be measured at recruitment (24 weeks of gestation) and at the end of follow-up (38 weeks of gestation))

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Brief Summary: Gestational diabetes mellitus (GDM) is a type of diabetes (high blood sugar) that occurs in pregnant women. This study will determine whether treating pregnant women who have mild GDM improves the health of their babies. The follow-up study will examine whether factors during the previous pregnancy (such as blood sugar during pregnancy) are associated with the woman and her child's health 4-9 years later.


Options:
A: Mean Fetal Weight at Birth (Immediately after delivery of fetus)
B: 3rd trimester glycated hemoglobin (3rd trimester of pregnancy); total maternal weight gain (during pregnancy); severe maternal hypoglycemia (from enrollment to delivery); preeclampsia (during pregnancy or puerperium); cesarean section (at the end of pregnancy); gestational age at birth (at birth); preterm birth (at birth); birthweight (at birth); macrosomia (at birth); large-for-gestational age newborn (at birth); small-for-gestational age newborn (at birth); neonatal hypoglycemia (in the neonatal period); perinatal mortality (in the perinatal period); insulin treatment (from enrollment to delivery)
C: Number of Participants With Composite Neonatal Morbidity (Delivery through discharge of infant from hospital up to 120 days); Number of Children at the 5-10 Year Followup With BMI ≥ 95th Percentile for Age and Sex (Age 5-10 years)
D: Number of Participants Assessed for Glucose Control (fasting and 2 hour postprandial blood glucose)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Brief Summary: Gestational diabetes mellitus (GDM) is a type of diabetes (high blood sugar) that occurs in pregnant women. This study will determine whether treating pregnant women who have mild GDM improves the health of their babies. The follow-up study will examine whether factors during the previous pregnancy (such as blood sugar during pregnancy) are associated with the woman and her child's health 4-9 years later.


Options:
A: Number of Participants With Composite Neonatal Morbidity (Delivery through discharge of infant from hospital up to 120 days); Number of Children at the 5-10 Year Followup With BMI ≥ 95th Percentile for Age and Sex (Age 5-10 years)
B: Gestational Weight Gain (Delivery)
C: Maternal Weight Change (baseline to 2 weeks post partum)
D: Gestational weight gain (36 weeks)

Answer: A